Luminopia, Inc., a digital health company for treatments for neuro-visual disorders, announced a content licensing agreement with Spin Master Corp., a children’s entertainment company, to bring popular children’s series to pediatric amblyopia patients using Luminopia’s FDA-cleared prescription digital therapeutic.
Spin Master joins Luminopia’s growing roster of entertainment partners, expanding the company’s library of age-appropriate content for patients to watch during therapy.
Patients using Luminopia will now be able to watch beloved Spin Master series including “PAW Patrol,” “Unicorn Academy,” “Vida the Vet” and “Bakugan” within the virtual reality (VR) headset.
Amblyopia, commonly known as lazy eye, is the leading cause of vision loss in children and affects approximately one million pediatric patients nationwide.
For decades, the standard of care has been eye-patching, which requires children to cover their stronger eye for multiple hours each day while navigating daily activities with impaired vision. This can make learning, playing sports and socializing more difficult, often taking an emotional toll on kids and their families. Additionally, patients who do endure treatment with eye patches are often left with persistent vision impairment.
Luminopia offers a modern alternative to traditional amblyopia treatment approaches with an FDA-cleared therapy that allows amblyopia patients to watch television within a VR headset for one hour a day, six days a week, as treatment. Luminopia works differently than eye-patching and does not require children to cover their stronger eye; instead, it encourages the brain to use both eyes together.
“This partnership enhances our growing content library with programming that children already know and love,” said Scott Xiao, founder and CEO of Luminopia. “Access to familiar, age-appropriate entertainment can play an important role in helping families stay engaged during treatment, and Spin Master’s loved characters and stories are a natural fit for our patient population.”
“At Spin Master, we’re committed to creating meaningful entertainment experiences that resonate with children and families around the world,” said Caroline Tyre, Spin Master’s VP of Global Content Distribution. “Working with Luminopia, we’re supporting children in a meaningful new way, and helping to make treatment experiences more engaging for families.”
Luminopia is being prescribed at leading eye institutes, children’s hospitals and private practices across the U.S. Parents and guardians of children with amblyopia can speak with their eye care providers to learn more about Luminopia.
For more information, visit luminopia.com.
¹De Novo granted in Oct 2021, 510(k) clearance in Apr 2025 to expand the age range.
Indications for Use for Luminopia
Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4 to <13, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is intended for both previously treated and untreated patients. Luminopia is intended to be used as an adjunct to full-time refractive correction, such as glasses, which should also be worn under the HMD during Luminopia therapy. Luminopia is intended for prescription use only, in an at-home environment.
